AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7759705 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg body weight over 15 min)
Number of subjects: 12
Study 2405793 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (25.5 Gy in five to seven days)
Number of subjects: 471
Study 2405793 — intervention group
Group type: COMPARATOR
Intervention: Postoperative irradiation (60 Gy in a total of 8 weeks)
Number of subjects: 471
Study 2405793 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation
Number of subjects: 471
Study 2405793 — intervention group
Group type: COMPARATOR
Intervention: Postoperative irradiation
Number of subjects: 471
Study 2405793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 471
Study 7011354 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 21
Study 7011354 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined infusion of aminophylline and salbutamol
Number of subjects: 21
Study 7011354 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 21
Study 31797848 — intervention group
Group type: EXPERIMENTAL
Intervention: Punica granatum
Number of subjects: 80
Study 31797848 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminalia chebula
Number of subjects: 80
Study 31797848 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitis vinifera
Number of subjects: 80
Study 31797848 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 29061624 — intervention group
Group type: EXPERIMENTAL
Intervention: video+prompt card
Number of subjects: 0
Study 29061624 — intervention group
Group type: EXPERIMENTAL
Intervention: decision aids+training
Number of subjects: 0
Study 29061624 — intervention group
Group type: EXPERIMENTAL
Intervention: video+prompt card and decision aids+training
Number of subjects: 0
Study 29061624 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 0
Study 26324395 — intervention group
Group type: EXPERIMENTAL
Intervention: Family/friend recommendations for mammograms within the last year
Number of subjects: 539
Study 26324395 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived mammography norms
Number of subjects: 539
Study 26324395 — intervention group
Group type: EXPERIMENTAL
Intervention: Support
Number of subjects: 539
Study 23399956 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest neighborhood socioeconomic status (nSES) quintile
Number of subjects: 74179
Study 23399956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever-smoking rates
Number of subjects: 74179
Study 21953682 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg)
Number of subjects: 20
Study 19452376 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 6 mg/day
Number of subjects: 26
Study 19452376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 15994253 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nebulised salbutamol
Number of subjects: 18
Study 15994253 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 18
Study 14521803 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent paclitaxel
Number of subjects: 0
Study 14521803 — intervention group
Group type: COMPARATOR
Intervention: Platinum/paclitaxel-based chemotherapy
Number of subjects: 0
Study 10228090 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil
Number of subjects: 110
Study 8686816 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous propofol anaesthesia (median total dose of propofol 710 mg)
Number of subjects: 20
Study 8686816 — intervention group
Group type: COMPARATOR
Intervention: Combined isoflurane anaesthesia (median end-expiratory concentration of isoflurane 0.45 vol %)
Number of subjects: 20
Study 8686816 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous propofol anaesthesia
Number of subjects: 20
Study 1839799 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant antibiotic‐anti‐inflammatory therapy
Number of subjects: 40
Study 1839799 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 40
Study 6633131 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser treatment
Number of subjects: 79
Study 6633131 — intervention group
Group type: COMPARATOR
Intervention: No specific treatment (Control)
Number of subjects: 79
Study 30550775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustainability via Active Garden Education (SAGE) intervention
Number of subjects: 20
Study 30550775 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGE intervention
Number of subjects: 20
Study 28537652 — intervention group
Group type: EXPERIMENTAL
Intervention: VLCKD1 (50% protein intake replaced with synthetic amino acids)
Number of subjects: 0
Study 28537652 — intervention group
Group type: COMPARATOR
Intervention: VLCKD2 (placebo)
Number of subjects: 0
Study 26814618 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity chemotherapeutic regimen
Number of subjects: 61
Study 25007361 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT 50 mg
Number of subjects: 775
Study 25007361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 775
Study 22687392 — intervention group
Group type: EXPERIMENTAL
Intervention: modafinil 200 mg daily
Number of subjects: 23
Study 22687392 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study 19735903 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid rotation using equianalgesic dose tables
Number of subjects: 0
Study 19735903 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting dose of new opioid based on relative potency
Number of subjects: 0
Study 17623486 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk supplemented with 3 g CLA (cis-9, trans-11 and trans-10, cis-12)
Number of subjects: 60
Study 17623486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15886218 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (300 microg b.i.d.) added to diuretics (furosemide and spironolactone)
Number of subjects: 20
Study 15886218 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide alone
Number of subjects: 20
Study 15886218 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of diuretics
Number of subjects: 20
Study 15886218 — intervention group
Group type: COMPARATOR
Intervention: Diuretics (furosemide and spironolactone)
Number of subjects: 20
Study 11952509 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmacure PS06/Evaflux Eval 5A (Kuraray)
Number of subjects: 4
Study 11952509 — intervention group
Group type: COMPARATOR
Intervention: Plasmaflo OP05W/Cascadeflo AC1770 (Asahi)
Number of subjects: 4
Study 9797095 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine evaluation between days 2 and 5 of a spontaneous menstrual cycle
Number of subjects: 48
Study 9797095 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine evaluation between days 22 and 25 of a spontaneous menstrual cycle
Number of subjects: 48
Study 8587482 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (16 mg.d‐1)
Number of subjects: 22
Study 8587482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8587482 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol with resistance exercise
Number of subjects: 22
Study 2676872 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin (1 to 3 mg t.i.d.)
Number of subjects: 48
Study 2676872 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (10 to 40 mg t.i.d.)
Number of subjects: 48
Study 2676872 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin
Number of subjects: 48
Study 2676872 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin and Propranolol
Number of subjects: 48
Study 2676872 — intervention group
Group type: COMPARATOR
Intervention: Bunazosin vs Propranolol
Number of subjects: 48
Study 367426 — intervention group
Group type: EXPERIMENTAL
Intervention: extra‐amniotic prostaglandin E2 gel
Number of subjects: 60
Study 367426 — intervention group
Group type: COMPARATOR
Intervention: oral prostaglandin E2
Number of subjects: 60
Study 367426 — intervention group
Group type: COMPARATOR
Intervention: intravaginal prostaglandin E2
Number of subjects: 60
Study 367426 — intervention group
Group type: COMPARATOR
Intervention: intravenous oxytocin
Number of subjects: 60
Study 31655422 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise + Far Infrared (FIR)
Number of subjects: 0
Study 31655422 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 28550827 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (pantoprazol, amoxicillin, and clarithromycin 12/12 hours for 14 days)
Number of subjects: 60
Study 28550827 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (pantoprazol 12/12 hours for 10 days, amoxicillin 12/12 hours for days 1-5, and clarithromycin plus metronidazol 12/12 hours during days 6-10)
Number of subjects: 60
Study 28550827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco consumption
Number of subjects: 60
Study 26111333 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics (oral amoxicillin 50 mg/kg/day for 5 days)
Number of subjects: 518
Study 26111333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study 23221573 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FXCO) - 20.6 g ALA/d
Number of subjects: 36
Study 23221573 — intervention group
Group type: COMPARATOR
Intervention: High-oleic acid canola oil (HOCO) - 2.4 g ALA/d
Number of subjects: 36
Study 23221573 — intervention group
Group type: COMPARATOR
Intervention: Western diet (WD) - 1.3 g ALA/d
Number of subjects: 36
Study 23221573 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 36
Study 20666881 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 431
Study 20666881 — intervention group
Group type: EXPERIMENTAL
Intervention: GP use of CRP point of care test
Number of subjects: 431
Study 20666881 — intervention group
Group type: EXPERIMENTAL
Intervention: GP communication skills training
Number of subjects: 431
Study 20666881 — intervention group
Group type: EXPERIMENTAL
Intervention: GP use of both CRP tests and communication skills training
Number of subjects: 431
Study 19796303 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% H(2)O(2) gel with light enhancement
Number of subjects: 33
Study 19796303 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% H(2)O(2) gel alone
Number of subjects: 33
Study 19796303 — intervention group
Group type: COMPARATOR
Intervention: Light alone with no peroxide
Number of subjects: 33
Study 16414461 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented subscapularis transposition
Number of subjects: 61
Study 16414461 — intervention group
Group type: COMPARATOR
Intervention: Subscapularis transposition alone
Number of subjects: 61
Study 16414461 — intervention group
Group type: COMPARATOR
Intervention: Intact rotator cuffs
Number of subjects: 61
Study 14703424 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tramadol
Number of subjects: 60
Study 14703424 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tramadol plus 0.1 mg droperidol
Number of subjects: 60
Study 10797611 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin for 16 weeks
Number of subjects: 55
Study 8866385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff around the finger
Number of subjects: 55
Study 8866385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff around the wrist
Number of subjects: 55
Study 8866385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff around the large arm
Number of subjects: 55
Study 1290441 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block using 20 ml of 1% lignocaine
Number of subjects: 0
Study 1290441 — intervention group
Group type: COMPARATOR
Intervention: Uterosacral block using 2 ml of 2% lignocaine
Number of subjects: 0
Study 6421138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (IC STK)
Number of subjects: 55
Study 6421138 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary nitroglycerin (IC NTG)
Number of subjects: 55
Study 6421138 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal occlusion patients
Number of subjects: 55
Study 31722585 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmony® prenatal Test
Number of subjects: 6510
Study 31722585 — intervention group
Group type: COMPARATOR
Intervention: HB‐cfDNA test
Number of subjects: 6510
Study 29920941 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm hand bath at 40°C for 10 min
Number of subjects: 40
Study 29920941 — intervention group
Group type: COMPARATOR
Intervention: No hand bath
Number of subjects: 40
Study 30357270 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy
Number of subjects: 776
Study 30357270 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 776
Study 27028981 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine (48 mg/d)
Number of subjects: 36
Study 27028981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24766999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 0
Study 24766999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22235353 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg)
Number of subjects: 200
Study 22235353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg)
Number of subjects: 200
Study 22235353 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg) in co-infected children with O. viverrini
Number of subjects: 200
Study 22235353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg) in co-infected children with O. viverrini
Number of subjects: 200
Study 19515110 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI (lansoprazole 15 mg/d)
Number of subjects: 100
Study 19515110 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional therapies)
Number of subjects: 100
Study 17459275 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative modalities
Number of subjects: 0
Study 17459275 — intervention group
Group type: COMPARATOR
Intervention: Active monitoring
Number of subjects: 0
Study 17459275 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention for locally advanced disease
Number of subjects: 0
Study 17459275 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of advanced disease
Number of subjects: 0
Study 16078671 — intervention group
Group type: COMPARATOR
Intervention: 50 mg sertraline daily for 12 weeks
Number of subjects: 72
Study 16078671 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sertraline daily plus 50 mg sildenafil as needed for 12 weeks
Number of subjects: 72
Study 11953346 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor omeprazole
Number of subjects: 0
Study 11953346 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 11574790 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus BAL
Number of subjects: 26
Study 11574790 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 26
Study 9133510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 80 mg/d
Number of subjects: 188
Study 9133510 — intervention group
Group type: COMPARATOR
Intervention: Cholesterol-lowering diet plus placebo
Number of subjects: 188
Study 7971287 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 102
Study 7971287 — intervention group
Group type: COMPARATOR
Intervention: Bone scintigraphy (BSc)
Number of subjects: 102
Study 3653876 — intervention group
Group type: EXPERIMENTAL
Intervention: Burkitt's lymphoma
Number of subjects: 608
Study 3653876 — intervention group
Group type: EXPERIMENTAL
Intervention: non-Burkitt's lymphoma
Number of subjects: 608
Study 3653876 — intervention group
Group type: COMPARATOR
Intervention: Reference diagnoses
Number of subjects: 608
Study 3653876 — intervention group
Group type: COMPARATOR
Intervention: Consensus review diagnoses
Number of subjects: 608
Study 29111919 — intervention group
Group type: EXPERIMENTAL
Intervention: Education-based intervention (3 sessions during the second trimester)
Number of subjects: 90
Study 29111919 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 29111919 — intervention group
Group type: EXPERIMENTAL
Intervention: Education-based intervention
Number of subjects: 90
Study 29231408 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint herbal application of huiyao tongluo dingtong san
Number of subjects: 96
Study 29231408 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 96
Study 29231408 — intervention group
Group type: COMPARATOR
Intervention: Tender point herbal application
Number of subjects: 96
Study 24720340 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurotron Venus cochlear implants
Number of subjects: 15
Study 24720340 — intervention group
Group type: COMPARATOR
Intervention: Cochlear Nucleus CI24
Number of subjects: 15
Study 23684673 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent (BES)
Number of subjects: 3235
Study 23684673 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 3235
Study 20625026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavioral weight loss program
Number of subjects: 338
Study 20625026 — intervention group
Group type: COMPARATOR
Intervention: Structured health education program (control)
Number of subjects: 338
Study 18936492 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecalibacterium prausnitzii (live or supernatant)
Number of subjects: 0
Study 18936492 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecalibacterium prausnitzii supernatant
Number of subjects: 0
Study 18936492 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecalibacterium prausnitzii
Number of subjects: 0
Study 16652049 — intervention group
Group type: EXPERIMENTAL
Intervention: Interruption of antiretroviral medication
Number of subjects: 36
Study 16652049 — intervention group
Group type: COMPARATOR
Intervention: Continuation of antiretroviral therapy
Number of subjects: 36
Study 12854102 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-layer compression bandaging
Number of subjects: 200
Study 12854102 — intervention group
Group type: COMPARATOR
Intervention: Usual system of care
Number of subjects: 200
Study 11305138 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 75
Study 11305138 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 75
Study 11305138 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 75
Study 11305138 — intervention group
Group type: EXPERIMENTAL
Intervention: All three anesthetics
Number of subjects: 75
Study 8641639 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous immunoglobulins (IVIG) 300 mg/kg every 4 weeks for 6 months
Number of subjects: 42
Study 8641639 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous immunoglobulins (IVIG)
Number of subjects: 42
Study 8641639 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 42
Study 1497105 — intervention group
Group type: EXPERIMENTAL
Intervention: Group parent training
Number of subjects: 0
Study 29808305 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-guided hemorrhoidal artery ligation/mucopexy (DGHAL) using THD™ (104 patients) and HAL-RAR™ (89 patients)
Number of subjects: 377
Study 29808305 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular stapled hemorrhoidopexy (CSH) using PPH-03™ (106 patients) and HEM™ (78 patients)
Number of subjects: 377
Study 29808305 — intervention group
Group type: COMPARATOR
Intervention: Doppler-guided hemorrhoidal artery ligation/mucopexy (DGHAL)
Number of subjects: 377
Study 29808305 — intervention group
Group type: COMPARATOR
Intervention: Circular stapled hemorrhoidopexy (CSH)
Number of subjects: 377
Study 26410591 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV)
Number of subjects: 53
Study 26410591 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressive therapy
Number of subjects: 53
Study 26410591 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 53
Study 23983132 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced monitoring
Number of subjects: 10
Study 23983132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 10
Study 22018394 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured antenatal training programme attended in mid-pregnancy
Number of subjects: 1193
Study 22018394 — intervention group
Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 1193
Study 20307824 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month low-moderate-intensity strength training program (2 sessions/week)
Number of subjects: 22
Study 20307824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study 18290777 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) monotherapy for 12 weeks
Number of subjects: 20
Study 18290777 — intervention group
Group type: COMPARATOR
Intervention: Combination of ATRA and PegIFN‐alpha2a for 12 weeks
Number of subjects: 20
Study 16595757 — intervention group
Group type: COMPARATOR
Intervention: Control (weight maintenance diet)
Number of subjects: 48
Study 16595757 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (25% calorie restriction of baseline energy requirements)
Number of subjects: 48
Study 16595757 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction with exercise (12.5% calorie restriction plus 12.5% increase in energy expenditure by structured exercise)
Number of subjects: 48
Study 16595757 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-calorie diet (890 kcal/d until 15% weight reduction, followed by a weight maintenance diet)
Number of subjects: 48
Study 14614633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (15 mg/kg/day) alone
Number of subjects: 43
Study 14614633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (15 mg/kg/day) plus low-dose aspirin (100 mg/day)
Number of subjects: 43